XDNA Holdings — Kelly CRISPR & Gene Editing Technology ETF
All 25 reported holdings of Kelly CRISPR & Gene Editing Technology ETF (XDNA) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| CRISPR Therapeutics AG | 14.70% | $380.23K |
| Beam Therapeutics Inc | 13.36% | $345.55K |
| Thermo Fisher Scientific Inc | 9.93% | $256.80K |
| Intellia Therapeutics Inc | 8.73% | $225.66K |
| Prime Medicine Inc | 6.05% | $156.42K |
| Editas Medicine Inc | 5.87% | $151.70K |
| Caribou Biosciences Inc | 4.94% | $127.87K |
| Verve Therapeutics Inc | 4.35% | $112.44K |
| Poseida Therapeutics Inc | 4.28% | $110.57K |
| AbbVie Inc | 4.01% | $103.66K |
| Sanofi SA | 3.28% | $84.85K |
| Novartis AG | 3.07% | $79.49K |
| Allogene Therapeutics Inc | 3.00% | $77.55K |
| Agilent Technologies Inc | 2.84% | $73.36K |
| 2seventy bio Inc | 1.75% | $45.24K |
| Sangamo Therapeutics Inc | 1.69% | $43.65K |
| Bristol-Myers Squibb Co | 1.63% | $42.17K |
| Vertex Pharmaceuticals Inc | 1.54% | $39.74K |
| Regeneron Pharmaceuticals Inc | 1.34% | $34.60K |
| Illumina Inc | 1.21% | $31.40K |
| Precision BioSciences Inc | 0.86% | $22.25K |
| Qiagen NV | 0.71% | $18.44K |
| Biogen Inc | 0.51% | $13.11K |
| First American Government Obli | 0.19% | $4.85K |
| First American Treasury Obliga | 0.19% | $4.85K |
XDNA overview: performance, fees, allocation and SEC filings